VintaBio

VintaBio delivers customized process development and GMP manufacturing services for cell and gene therapy. The company's development and manufacturing team has over a century of experience in the cell and gene therapy space and has been involved in the development of some of the most advanced therapies on the market. Situated in the historic Navy Yards of Philadelphia, an epicenter of cell and gene therapy innovation, VintaBio specializes in developing and manufacturing consistent, high-quality viral vectors, addressing an underserved area of CGT development. Co-founded by Junwei Sun and Dr. Shangzhen Zhou, who were pivotal in the development of the AAV vectors behind the first two FDA-approved gene therapies and the lentiviral vector for the first FDA-approved cell therapy, the company has raised a substantial $64 million in venture funding. This funding has facilitated the development of a new 22,500 square foot facility in Philadelphia, specifically designed for efficient cell and gene therapy manufacturing. The latest $64.00M Venture Round investment on 11th April 2023 was led by Decheng Capital.